===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Amendment No. 1
Under the Securities Exchange Act of 1934
OSI PHARMACEUTICALS, INC.
(Formerly Oncogene Science, Inc.)
----------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
- ---------------------------------------------------------------------------
(Title of Class of Securities)
682305 10 7
-----------------
(CUSIP Number)
November 30, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which theis Schedule
is filed:
[ ] Rule 13d-1(b)
[ x ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
===========================================================================
Page 1 of 9
Exhibit Index is located at page 8
<PAGE> 2
CUSIP No. 682305 10 7
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 661,400
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 661,400
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 661,400
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 3.1%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 3
CUSIP No. 682305 10 7 13G
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 661,400
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 661,400
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 661,400
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 3.1%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 4
CUSIP No. 682305 10 7 13G
This Amendment No. 1 to the Statement on Schedule 13G with respect to
the Common Stock of OSI Pharmaceuticals, Inc. (formerly Oncogene Science, Inc.)
(the "Issuer"), is filed jointly by Aventis Pharmaceuticals Inc., a Delaware
corporation ("Aventis"), and HMR Pharma, Inc., a Delaware corporation
("Pharma"), to reflect the change of name of Hoechst Marion Roussel, Inc., to
Aventis Pharmaceuticals Inc. and to report the termination of the Schedule 13G
filing obligation of Aventis and Pharma with respect to beneficial ownership of
securities of the Issuer. The following items of the Statement on Schedule 13G
are hereby amended to read as follows:
ITEM 2(a). NAME OF PERSON FILING:
- ---------- ----------------------
Aventis Pharmaceuticals Inc.
HMR Pharma, Inc.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ---------- ------------------------------------------------------------
Aventis Pharmaceuticals Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- ---------- ------------
Delaware As To Both Aventis Pharmaceuticals Inc. And
HMR Pharma, Inc.
<PAGE> 5
CUSIP No. 682305 10 7 13G
ITEM 4. OWNERSHIP
- ------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 7/31/99 661,400 Shares Of Common Stock. A Warrant to Purchase
up to 500,000 Warrant Shares at $5.50 Per Share expired on December
10, 1999.
(b): PERCENT OF CLASS:
3.1%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 661,400
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the 661,400
disposition of:
(iv) Shared power to dispose or to direct the 0
disposition of:
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
- ------- ---------------------------------------------
If this statement is being filed to report the fact that as of the
date hereof the reporting persons have ceased to be the beneficial owner of more
than five percent of the class of securities, check the following: [ x ]
<PAGE> 6
CUSIP No. 682305 10 7 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
----------------------------
Rebecca R. Tilden
Vice President and Secretary
<PAGE> 7
CUSIP No. 682305 10 7 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
----------------------------
Rebecca R. Tilden
Vice President and Assistant Secretary
<PAGE> 8
CUSIP No. 682305 10 7 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Agreement to File Jointly dated December 9
22, 1999, by and between Aventis
Pharmaceuticals Inc. and HMR Pharma, Inc.
<PAGE> 9
CUSIP No. 682305 10 7 13G
EXHIBIT 99.A
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G is filed on behalf of each of us.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
-------------------------------
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Assistant
Secretary
